FORM 4

Check this box if no longer subject

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | |
|--------------|--|-----------|--|--|--|--|--|--|
| OMB Number: | | 3235-0287 | | | | | | |
| - | | | | | | | | |

| to Section 16. | Form 4 or Form 5 ay continue. See | | led pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | 4 | | Estimated av | 0 |
|---|--------------------------------------|-------------------------|--|--------------------------|------------|---------------|---|
| 1. Name and Address of Reporting Person* Glass Geoffrey Michael (Last) (First) (Middle) C/O AVADEL PHARMACEUTICALS PLC 10 EARLSFORT TERRACE | | (Middle) UTICALS PLC | 2. Issuer Name and Ticker or Trading Symbol <u>AVADEL PHARMACEUTICALS PLC</u> [AVDL] 3. Date of Earliest Transaction (Month/Day/Year) 05/31/2022 | Officer (give title Othe | | | son(s) to Issuer 10% Owner Other (specify below) |
| (Street) DUBLIN 2 (City) | L2 (State) | D02 T380 (Zip) | 4. If Amendment, Date of Original Filed (Month/Day/Year) 06/02/2022 | 6. Indiv Line) X | Form filed | l by One Repo | g (Check Applicable orting Person n One Reporting |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | | 4. Securities Disposed Of 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | Form: Direct | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---|------|---|------------------------------------|---------------|-------------------------------|---|--------------|---|
| | | | Code | v | Amount | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | (1150. 4) |
| ADSs ⁽¹⁾ | 05/31/2022 | | Р | | 45,000 | Α | \$2 .14 ⁽²⁾ | 45,000 | Ι | By Trust ⁽³⁾ |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| | | | | | | | | • • | | | | , | | | |
|---|---|--|---|------------------------------|---|-----------|-----|--|---|-------|---|--|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | of Expira | | 6. Date Exerc Expiration Da (Month/Day/Y | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$2.10 to \$2.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

3. These ADSs are held by The Geoffrey Glass Trust of which the reporting person is a co-trustee. The reporting person is the sole beneficiary of the trust.

Remarks:

The Form 4 filed on June 2, 2022 inadvertently reported that the transaction occurred on June 1, 2022. The transaction occurred on May 31, 2022.

| /s/ Jerad G. Seurer, | as |
|----------------------|----|
| Attorney-in-Fact | |

** Signature of Reporting Person Date

06/03/2022

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.